Potent Thiophene Antagonists of Human Complement C3a Receptor with Anti-Inflammatory Activity
Authors:
- Jessica A. RowleyJRJessica A. Rowley
- Robert C. ReidRRRobert C. Reid
- Eunice K. Y. PoonEPEunice K. Y. Poon
- Kai-Chen WuKWKai-Chen Wu
- Junxian LimJLJunxian Lim
- Rink-Jan LohmanRLRink-Jan Lohman
- Johan K. HamidonJHJohan K. Hamidon
- Mei-Kwan YauMYMei-Kwan Yau
- Maria A. HaliliMHMaria A. Halili
- Thomas DurekTDThomas Durek
- Abishek IyerAIAbishek Iyer
- David P. FairlieDFDavid P. Fairlie
- 7 January 2020
- journal article
- research article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 63 (2) , 529-541
Abstract
Structure–activity relationships for a series of small-molecule thiophenes resulted in potent and selective antagonism of human Complement C3a receptor. The compounds are about 100-fold more potent than the most reported antagonist SB290157. A new compound JR14a was among the most potent of the new antagonists in vitro, assessed by (a) inhibition of intracellular calcium release (IC50 10 nM) induced in human monocyte-derived macrophages by 100 nM C3a, (b) inhibition of β-hexosaminidase secretion (IC50 8 nM) from human LAD2 mast cells degranulated by 100 nM C3a, and (c) selectivity for human C3aR over C5aR. JR14a was metabolically stable in rat plasma and in rat liver microsomes and efficacious in rats when given orally to suppress rat paw inflammation, macrophage and mast cell activation, and histopathology induced by intraplantar paw administration of a C3aR agonist. Potent C3aR antagonists are now available for interrogating C3a receptor activation and suppressing C3aR-mediated inflammation in mammalian physiology and disease.Keywords
Funding Information
- National Health and Medical Research Council (1027369, 1028423, 1084018, 1117017, 1145372)
- Australian Research Council (CE140100011, DP130100629, DP180103244)
- Queensland Government
- University of Queensland
This publication has 42 references indexed in Scilit:
- Efficient chemical synthesis of human complement protein C3aChemical Communications, 2013
- Measuring Mast Cell Mediator ReleaseCurrent Protocols in Immunology, 2010
- Novel Agonists and Antagonists for Human Protease Activated Receptor 2Journal of Medicinal Chemistry, 2010
- Complement: a key system for immune surveillance and homeostasisNature Immunology, 2010
- Animal research: Reporting in vivo experiments: The ARRIVE guidelinesBritish Journal of Pharmacology, 2010
- Selective Hexapeptide Agonists and Antagonists for Human Complement C3a ReceptorJournal of Medicinal Chemistry, 2010
- Complement regulators and inhibitory proteinsNature Reviews Immunology, 2009
- The C3a Anaphylatoxin Receptor Is a Key Mediator of Insulin Resistance and Functions by Modulating Adipose Tissue Macrophage Infiltration and ActivationDiabetes, 2009
- Function, structure and therapeutic potential of complement C5a receptorsBritish Journal of Pharmacology, 2007
- Anaphylatoxin inactivator of human plasma: its isolation and characterization as a carboxypeptidaseJournal of Clinical Investigation, 1970